Frunevetmab（Cat No.:I042096）is an investigational monoclonal antibody primarily being developed for the treatment of osteoarthritis in dogs. It targets nerve growth factor (NGF), a protein that plays a key role in pain signaling and inflammation associated with joint diseases. By binding to NGF, frunevetmab aims to reduce pain and inflammation, improving mobility and quality of life for dogs suffering from osteoarthritis. It is currently undergoing clinical trials to evaluate its safety and efficacy in veterinary medicine, with the potential to provide a novel treatment option for managing chronic pain in animals.
